Lee’s Pharmaceutical FY26 H1 profit attributable to owners climbs 41.4% to HK$ 95.01 million; revenue rises 14.6% to HK$ 796.57 million

• Lee's Pharmaceutical posted a 41.4% rise in profit attributable to shareholders to HK$ 95.01 million for the six months ended June 30.
• Revenue climbed 14.6% to HK$ 796.57 million, reflecting stronger licensed-in product sales and growth in proprietary and generic products.
• Gross profit rose 24.3% to HK$ 447.45 million, lifting gross margin 4.4 percentage points to 56.2% on improved mix and manufacturing gains.
• Basic earnings per share increased 41.5% to 16.14 HK cents; interim dividend was raised to 3.5 HK cents per share.
• Management highlighted the US Staccato inhalation platform buildout, with Fremont producing qualification batches, and said H2 2026 starts from a stronger base.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308490), on August 31, 2026, and is solely responsible for the information contained therein.